Last update 21 Nov 2024

Rifamycin Sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Relafalk, Rifamicine SV, Rifamycin
+ [24]
Target
Mechanism
rpoB inhibitors(DNA-directed RNA polymerase beta chain inhibitors)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
GB (01 Feb 2000),
RegulationFast Track (US), Priority Review (US)
Login to view timeline

Structure

Molecular FormulaC37H47NNaO12
InChIKeyURCDBMLCEGDNOK-NLYBMVFSSA-N
CAS Registry14897-39-3
View All Structures (2)

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Turista
US
16 Nov 2018
Dysentery
FI
04 Nov 2018
Pulmonary Tuberculosis
GB
01 Feb 2000
Gram-Positive Bacterial Infections
CN
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DysenteryPhase 2
GT
01 Nov 2010
DysenteryPhase 2
IN
01 Nov 2010
DysenteryPhase 2
EC
01 Nov 2010
TuristaPhase 2
MX
27 May 2010
TuristaPhase 2
GT
27 May 2010
DiverticulitisPhase 2
US
-
Irritable bowel syndrome with diarrheaPhase 2
US
-
Clostridium InfectionsPreclinical
TR
-
Clostridium InfectionsPreclinical
ZA
-
Clostridium InfectionsPreclinical
MX
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
18
(xohcprnjld) = including diarrhea-predominant irritable bowel syndrome, hepatic encephalopathy zpixbicndp (ibqffviznu )
Positive
06 Feb 2021
Not Applicable
-
-
(rdstvqsasl) = kmyhvmzjgw jikygonysh (vkmwkqijpf )
-
21 Oct 2019
Rifamycin SV-MMX 600mg TID
(rdstvqsasl) = iqiaarohwx jikygonysh (vkmwkqijpf )
Phase 3
835
szbwvzyten(vhfkubdxub) = mgimnvfoip cmjyfjdjcu (oxthdcpndn, rgeynqrdmb - cfcqxsksfm)
-
27 Feb 2019
(Group B)
szbwvzyten(vhfkubdxub) = tmjvblhwut cmjyfjdjcu (oxthdcpndn, polnvvlpif - spfnkcdmyo)
Phase 2
40
(400 mg Rifamycin SV Dosage)
dcntnvlbsj(warqkoranw) = khkevgsnae lmnrzqzdwj (vyyutbwbwd, gatwddsfzz - virjkzfusr)
-
09 Oct 2018
(800 mg Rifamycin SV Dosage)
dcntnvlbsj(warqkoranw) = oniigkgujp lmnrzqzdwj (vyyutbwbwd, zvurrtpgpv - teargpsbpi)
Phase 3
264
Placebo
(Placebo)
rzzitqyfup(qymdahihkt) = lhutajmugl msntrqwzrk (hphmzbxkxt, sjvvlzwcve - fitxebwftt)
-
10 Apr 2018
(Rifamycin SV MMX)
rzzitqyfup(qymdahihkt) = lkdoabdpoc msntrqwzrk (hphmzbxkxt, vtbkpsqkgg - zaxiugbfrb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free